| Literature DB >> 33137011 |
Olivia T Van Gerwen1, Andres F Camino2, Lorelei N Bourla3, Davey Legendre4, Christina A Muzny1.
Abstract
ABSTRACT: Metronidazole and other 5-nitroimidazoles are the mainstay of Trichomonas vaginalis treatment, with few efficacious and safe treatment options available outside of this class. Patients with trichomoniasis and a history of a clinically confirmed hypersensitivity reaction to 5-nitroimidazoles present a management challenge for clinicians. The first step in managing such patients is metronidazole desensitization. In situations where this cannot be performed or tolerated, treatment with alternative regimens outside of the 5-nitroimidazole class, such as intravaginal boric acid or paromomycin, may be possible.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33137011 PMCID: PMC8081757 DOI: 10.1097/OLQ.0000000000001326
Source DB: PubMed Journal: Sex Transm Dis ISSN: 0148-5717 Impact factor: 3.868